Selected concepts on ethics in biopharmaceutical innovation

Kadour Ghanemi, Shuangsheng Yan
{"title":"Selected concepts on ethics in biopharmaceutical innovation","authors":"Kadour Ghanemi, Shuangsheng Yan","doi":"10.15406/mojpb.2017.06.00204","DOIUrl":null,"url":null,"abstract":"Responsible research and innovation (RRI) is among the most important issues that have generated a huge debate within the political and social milieu, which became an overall case for the biggest EU Research and innovation program ever Horizon [1]. Responsible research and innovation is among the important doctrines for the sustainability of the company [2]. Ethics and the biopharmaceutical responsible innovation is a paradigm of a sector where the ethics and responsibility of health professionals is inevitably linked to public and private life. The biopharmaceutical research, development and marketing responsibilities are taken by the pharmacists, directors and managers of the biopharmaceutical company, all are a combined healthcare team which work together and have a lot of combined bio drugs innovation’s issues [3]. Now we are in age where the bio pharmacy improves with a high rapidity, a new generation of several bio drugs is discovered for improving survival rates, a lot of chronic and even fatal maladies are promised now with a new series of bio drugs to enhance the patient health [4-7]. The role of this staff (bio pharmacists, directors, and managers) is to minimize the risks and the harm of the new developed bio drugs during the clinical trials process and during the patient’s consumption of this new treatment, also to secure the efficacy of the new bio drug and guarantee that the novel discovered bio drugs can be used safely. Moreover, to facilitate its access and also to strengthen the country’s economy in order to serve the humanity interests and boosting the healthcare progress in general [8]. However, the biopharmaceutical innovation can be seen as a junction between business and health, this gives rise to a several series of ethical and responsibility issues and a dire need to make some rules, standards and principles for the bio drug innovation’s process built on rational and virtues.","PeriodicalId":18585,"journal":{"name":"MOJ proteomics & bioinformatics","volume":"85 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MOJ proteomics & bioinformatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/mojpb.2017.06.00204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Responsible research and innovation (RRI) is among the most important issues that have generated a huge debate within the political and social milieu, which became an overall case for the biggest EU Research and innovation program ever Horizon [1]. Responsible research and innovation is among the important doctrines for the sustainability of the company [2]. Ethics and the biopharmaceutical responsible innovation is a paradigm of a sector where the ethics and responsibility of health professionals is inevitably linked to public and private life. The biopharmaceutical research, development and marketing responsibilities are taken by the pharmacists, directors and managers of the biopharmaceutical company, all are a combined healthcare team which work together and have a lot of combined bio drugs innovation’s issues [3]. Now we are in age where the bio pharmacy improves with a high rapidity, a new generation of several bio drugs is discovered for improving survival rates, a lot of chronic and even fatal maladies are promised now with a new series of bio drugs to enhance the patient health [4-7]. The role of this staff (bio pharmacists, directors, and managers) is to minimize the risks and the harm of the new developed bio drugs during the clinical trials process and during the patient’s consumption of this new treatment, also to secure the efficacy of the new bio drug and guarantee that the novel discovered bio drugs can be used safely. Moreover, to facilitate its access and also to strengthen the country’s economy in order to serve the humanity interests and boosting the healthcare progress in general [8]. However, the biopharmaceutical innovation can be seen as a junction between business and health, this gives rise to a several series of ethical and responsibility issues and a dire need to make some rules, standards and principles for the bio drug innovation’s process built on rational and virtues.
生物制药创新中的伦理概念选择
负责任的研究与创新(RRI)是最重要的问题之一,在政治和社会环境中引发了巨大的争论,这成为欧盟有史以来最大的研究与创新项目Horizon的总体案例[1]。负责任的研究和创新是公司可持续发展的重要原则之一[2]。伦理和负责任的生物制药创新是卫生专业人员的伦理和责任不可避免地与公共和私人生活联系在一起的一个部门的范例。生物制药的研究、开发和营销责任由生物制药公司的药剂师、董事和经理承担,他们都是一个协同工作的联合医疗团队,有很多联合生物药物创新的问题[3]。现在我们正处于生物制药高速发展的时代,新一代的几种生物药物被发现来提高生存率,许多慢性甚至致命的疾病现在有了一系列新的生物药物来改善患者的健康[4-7]。这些工作人员(生物药师、主任、管理人员)的作用是将新开发的生物药物在临床试验过程和患者使用新疗法过程中的风险和危害降到最低,确保新开发的生物药物的疗效,保证新发现的生物药物可以安全使用。此外,为了方便其获取,也为了加强国家的经济,以服务于人类利益,促进医疗保健的总体进步[8]。然而,生物制药创新是商业与健康的结合点,这就产生了一系列的伦理和责任问题,迫切需要在理性和美德的基础上为生物制药创新过程制定一些规则、标准和原则。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信